0345 BZRA Hypnotic Receptor Specificity and Ability to Discontinue Chronic Hypnotic Use

Abstract Introduction Clinicians prescribing hypnotics remain concerned regarding the inability to discontinue after chronic use. In a controlled prospective study using self-administration choice procedures we tested whether BZRA hypnotic receptor specificity is predictive of discontinuation difficulty in clinical trial which insomnia subjects are instructed stop taking their medication 6 months nightly Methods DSM-V diagnosed subjects, aged 23-61 yrs, (n=41, 36 females), with no other sleep disorders, unstable medical or psychiatric diseases drug dependency completed trial. Following screening polysomnogram and MSLT, participants were randomized zolpidem XR 12.5 mg (n=16), eszopiclone 3 (n=11), placebo (n=14) for months. After months, use, over 2-week period, they but if necessary, self-administer either 1, 2, capsules assigned “blinded” (zolpidem 6.25 mg, placebo; 2 1 as respectively; placebos). Results Over 14 nights 21 took zero (51%) capsules; among 20 median total number chosen two weeks was 3. Most one capsule per night; > on given night. Overall, taken declined from week (p< .001). The group greater than (p<.005), between. also showed trend (p<.07) fail reduce use 2. Conclusion majority discontinued 6-month those rate non-hypnotic specific group. This first ­demonstration differential abuse liability BzRA hypnotics. Support (if any) NIDA, grant#: R01DA038177 awarded Dr. Roehrs.